融合瘤疫苗对人结肠转移癌免疫重建鼠的治疗作用

Dendritic cell/tumor hybrids enhance therapeutic efficacy against subcutaneously implanted colon cancer in severe combined immunodeficient mice

目的观察树突状细胞（DC）-结肠转移癌细胞融合疫苗对人结肠转移癌动物模型的治疗效果。方法用聚乙二醇（PEG）融合法将DC与人结肠转移癌SW620细胞制备成融合瘤疫苗，将融合瘤疫苗于左、有后足底、尾根部3点[含1×10^7细胞融合瘤疫苗的磷酸盐缓冲液（PBS）共150μl]接种在人免疫重建的严重联合免疫缺陷（SCID）小鼠皮下移植瘤模型，观察其在抑制肿瘤生长和延长生存期方面的作用。结果经融合瘤疫苗治疗，融合瘤疫苗治疗组小鼠皮下肿瘤体积生长速度慢于其他各对照组；融合瘤疫苗治疗组生存期为（109．00±17．17）d，明显长于单纯手术组（55．67±12．03）d、免疫重建单纯手术组（81．83±9．06）d、免疫重建肿瘤细胞冻融物治疗组（87．33±12．85）d，差异有统计学意义（P〈0．05）。结论DC／SW620细胞融合瘤疫苗具有抑制肿瘤生长，延长荷瘤小鼠生存期的作用。

Objective To investigate the antitumor effects of dendritomas fusion of dendritic cells （DC） and metastatic colon cancer SW620 cells in subcutanteously implanted colon cancer model with im- mune reconstitution in severe combined immunodeficient （SC1D） mice. Methods Dendritomas were gen- erated by fusing allogeneie blood-derived DCs with colon cancer SW620 cells using 50% polyethylene gly- col （PEG）, and SCID mice were randomly divided into 5 groups, subcutaneously injected with SW620 cells for the subcutaneously implanted colon cancer model. Diameter of the subcutaneous tumors and the survival days of models were analyzed. Results Tumor growth could be suppressed and survival eould be prolonged by DC/SW620 hybirds. In the subcutaneously implanted colon cancer models, the survival time in DC/SW620 hybieds-treated group （group D） was （109.00 -＋ 17. 17） days, longer than in group B （55.67 _＋ 12. 03） days, group C （81.83 -＋9. 06） days, and group E （87.33 ＋ 12. 85） days （P 〈0. 05）. Conclusion Tumor growth can be suppressed and survival can be prolonged by DC/SW620 hybirds.